Developing an optimal follow-up strategy based on the natural history of nonfunctioning pituitary adenomas.

ACTH = adrenocorticotropic hormone FSH = follicle-stimulating hormone LH = luteinizing hormone PA = pituitary adenoma PY = person-year TSH = thyroid-stimulating hormone VIS = visual impairment scale follow-up natural history nonfunctioning observation pituitary adenoma pituitary surgery

Journal

Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357

Informations de publication

Date de publication:
01 08 2019
Historique:
received: 27 08 2017
accepted: 05 04 2018
pubmed: 15 9 2018
medline: 21 11 2019
entrez: 15 9 2018
Statut: epublish

Résumé

The natural history and proper algorithm for follow-up testing of nonfunctioning pituitary adenomas (PAs) are not well known, despite their relatively high prevalence. The aim of this study was to suggest the optimal follow-up algorithm for nonfunctioning PAs based on their natural history. The authors followed up 197 patients with nonfunctioning PAs that had not been treated (including surgery and radiation therapy) at the time of detection, in a single center, between March 2000 and February 2017. They conducted a hormone test, visual field test, and MRI at the time of diagnosis and yearly thereafter. The overall median follow-up duration was 37 months. Microadenomas (n = 38) did not cause visual disturbance, pituitary apoplexy, or endocrine dysfunction. The incidence of patients with tumor volume growth ≥ 20% was higher for macroadenomas than microadenomas (13.8 vs 5.0 per 100 person-years [PYs], p = 0.002). The median time to any tumor growth was 4.8 years (95% CI 3.4-4.8 years) for microadenomas and 4 years (95% CI 3.3-4.2 years) for macroadenomas. The overall incidence of worsening visual function was 0.69 per 100 PYs. Patients with a tumor volume growth rate ≥ 0.88 cm3/year (n = 20) had a higher incidence of worsening visual function (4.69 vs 0.30 per 100 PYs, p < 0.001). The tumor growth rate of all microadenomas was < 0.88 cm3/year. The median time to tumor growth ≥ 20% was 3.3 years (95% CI 1.8-3.9 years) in patients with a tumor growth rate ≥ 0.88 cm3/year and 4.9 years (95% CI 4.6-7.2 years) in patients with a tumor growth rate < 0.88 cm3/year. The authors have devised a follow-up strategy based on the tumor volume growth rate as well as initial tumor volume. In patients with microadenomas, the next MRI study can be performed at 3 years. In patients with macroadenomas, the second MRI study should be performed between 6 months and 1 year to assess the tumor growth rate. In patients with a tumor growth rate ≥ 0.88 cm3/year, the MRI study should be performed within 2 years. In patients with a tumor growth rate < 0.88 cm3/year, the MRI study can be delayed until 4 years.

Identifiants

pubmed: 30215565
pii: 2018.4.JNS172148
doi: 10.3171/2018.4.JNS172148
doi:
pii:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

500-506

Commentaires et corrections

Type : ErratumIn

Auteurs

Jung Hee Kim (JH)

1Department of Internal Medicine.
2Pituitary Center.
4Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.

Yun-Sik Dho (YS)

2Pituitary Center.
3Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, and.

Yong Hwy Kim (YH)

2Pituitary Center.
3Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, and.

Jung Hyun Lee (JH)

2Pituitary Center.
3Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, and.

Ji Hyun Lee (JH)

1Department of Internal Medicine.

A Ram Hong (AR)

1Department of Internal Medicine.

Chan Soo Shin (CS)

1Department of Internal Medicine.
2Pituitary Center.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH